Nyxoah logo

Nyxoah(NYXH)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.9
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for NYXH

11/13/2026: NYXH (1-star) is currently NOT-A-BUY. Pass it for now.

Nyxoah is a growth-stage medical technology company developing the Genio system, a battery-free, minimally invasive neurostimulation treatment for obstructive sleep apnea. The company’s primary strength lies in its innovative, patient-friendly technology, which aims to provide an alternative for patients who cannot tolerate traditional CPAP therapy. Its main growth opportunity centers on successfully penetrating the large US market following its recent Nasdaq listing. Investors must balance this potential against significant execution risks, including intense competition from well-capitalized incumbents like Inspire Medical Systems and the need to scale commercial operations while remaining unprofitable. The stock is best suited for growth-oriented investors who can tolerate high volatility and long-term clinical development risks.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitNyxoah represents a high-growth opportunity in the medical device sector focused on a significant unmet need.
Momentum investorStrong fit while signal remains positiveThe stock's performance is tied to clinical and commercial catalysts that can drive significant price movement.
Value investorWeak fitThe company is currently unprofitable and trades based on future growth potential rather than current value metrics.
Dividend investorWeak fitNyxoah does not pay a dividend and is unlikely to do so in the near future.
Low-risk investorWeak fitThe high volatility and clinical risk inherent in a growth-stage medical device company are unsuitable for low-risk strategies.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighAs a growth-stage biotech/medtech stock, price swings are frequent based on news flow.
Valuation riskMedium / highValuation is highly dependent on long-term adoption projections that may not materialize.
Competition risk (Inspire Medical)HighIncumbents have established physician relationships and market presence.
Business qualityMediumThe company has a strong, innovative product but is still proving its commercial viability.
Dividend incomeLow / noneNo income is currently generated for shareholders.
Execution riskMedium / highScaling a commercial medical device organization requires complex logistical and sales execution.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 91.61M USD
Price to earnings Ratio -
1Y Target Price 2.8
Price to earnings Ratio -
1Y Target Price 2.8
Volume (30-day avg) 226.3K shares
Beta 1.02
52 Weeks Range 0.80 - 5.39
Updated Date 11/14/2026
52 Weeks Range 0.80 - 5.39
Updated Date 11/14/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.83

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -31.73%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
NYXH receives a 3-star rating based on the available scored pillars. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
NYXH has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, strong revenue growth (+121.6%) is partially offset by negative earnings growth (-52.1%), weak cash generation (FCF margin -681.6%), weak profitability (net margin -899.1%).

Financial Health Rating

★★★★★
NYXH's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 10.3%). Cash strength is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is NYXH's strongest growth driver at +121.6% FY2025 versus FY2024 (strong, 5 stars). By comparison, while earnings growth (-52.1%, negative) and free-cash-flow growth (-23.5%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 30.4% and approximately 51.6% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 33.27% supports management-shareholder alignment.

Unit Economics (Per $1K Revenue)

★★★★★
NYXH generates approximately $631 of gross profit, $-8,278 of operating income, and $-6,816 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -1.13% (Tax Credit)

Quantitative Style Profile

★★★★★
NYXH has a liquid profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedSmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Genio System SalesRevenue from the sale of the Genio neurostimulation device and related components to hospitals and clinics.The company makes money by selling its medical device directly to healthcare providers for patient treatment.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 58.31M
Price to Sales(TTM) 3.17
Enterprise Value 58.31M
Price to Sales(TTM) 3.17
Enterprise Value to Revenue 1.77
Enterprise Value to EBITDA -2
Shares Outstanding 101.84M
Shares Floating 52.55M
Shares Outstanding 101.84M
Shares Floating 52.55M
Percent Insiders 33.27
Percent Institutions 30.39

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.